Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LFZFX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ABBV-319
|
|||||
| Synonyms |
ABBV319; ABBV 319
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 3 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Phase 1
Follicular lymphoma [ICD11:2A80]
Phase 1
Lymphoid leukaemia [ICD11:2B33]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD19 ABBV319 IgG1 mAb
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Proprietary GRM agonist
|
Payload Info | ||||
| Therapeutic Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
Formyl-Ala-Ala
|
Linker Info | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.